CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- K36 Therapeutics (“K36”) has been selected as “Overall BioPharma Startup of the Year” in the third annual BioTech Breakthrough Awards Program ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
CAMBRIDGE, Mass., Aug. 7, 2025 /PRNewswire/ -- K36 Therapeutics, Inc. ("K36"), a privately held clinical-stage biotechnology company developing novel, targeted therapies for cancers with unmet medical ...
CAMBRIDGE, Mass., Dec. 4, 2023 /PRNewswire/ -- K36 Therapeutics, Inc. ("K36"), a clinical-stage biotech company focused on developing its first-in-class MMSET inhibitor KTX-1001 for t(4;14) multiple ...
K36 Therapeutics has come out of the gates with $30 million in venture funding to back a small-molecule oral treatment from Novartis. The Cambridge, Massachusetts, biotech emerged Thursday to take its ...
The MarketWatch News Department was not involved in the creation of this content. KTX-2001 being evaluated both as a monotherapy and in combination with darolutamide in metastatic castration-resistant ...
CAMBRIDGE, Mass., Sept. 16, 2025 /PRNewswire/ -- K36 Therapeutics, Inc. ("K36"), a privately held clinical-stage biotechnology company developing novel, targeted therapies for cancers with unmet ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results